An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention

Thrombosis Journal

Table 3 Multivariate analysis based on the therapeutic window

One-year outcome	IW^*	OW^†	HR	95%CI	P
	506	1203
	n(%)	n(%)
Net adverse clinical events	85 (16.8)	278 (23.1)	1.44	1.12–1.85	0.004
Ischemic events	11 (2.2)	34 (2.8)	1.34	0.68–2.64	0.403
Death	5 (1.0)	15 (1.2)	1.27	0.46–3.51	0.640
MI	5 (1.0)	15 (1.2)	1.30	0.47–3.59	0.608
ST	5 (1.0)	16 (1.3)	1.41	0.52–3.87	0.500
TVR	1 (0.2)	10 (0.8)	4.49	0.57–35.17	0.150
Bleeding events	80 (15.8)	248 (20.6)	1.33	1.03–1.72	0.028
Major + Minor	10 (2.0)	221 (1.8)	0.86	0.40–1.84	0.700
Minimal	70 (13.8)	226 (18.8)	1.38	1.05–1.81	0.022

Risk factors included in the analysis of net clinical outcome: Sex, age, BMI, Smoking, Hypertension, Diabetes, CABG history, PCI history, Hemoglobin, Platelet count, eGFR, APTT, INR; Risk factors included in the analysis of MACE: Sex, Age, BMI, Smoking, Hypertension, Diabetes, CABG history, PCI history; Risk factors included in the analysis of bleeding: Sex, Age, Hypertension, Diabetes, Hemoglobin, Platelet count, eGFR, INR, APTT
^* IW: 25.5% ≤ PL_ADP < 37.5%; ^† OW: PL_ADP < 25.5% or ≥ 37.5%

ISSN: 1477-9560